Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.

[1]  S. Lerakis,et al.  Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. , 2006, Journal of the American College of Cardiology.

[2]  D. Mann,et al.  The emerging role of statins in the treatment of heart failure. , 2006, Journal of the American College of Cardiology.

[3]  R. Brook,et al.  Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. , 2006, Journal of the American College of Cardiology.

[4]  D. Mozaffarian,et al.  The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. , 2005, The American journal of cardiology.

[5]  R. Califf,et al.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.

[6]  J. Liao,et al.  Rho GTPases, statins, and nitric oxide. , 2005, Circulation research.

[7]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[8]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[9]  J. Tu,et al.  Statin use and survival outcomes in elderly patients with heart failure. , 2005, Archives of internal medicine.

[10]  M. Pfeffer,et al.  Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes , 2004 .

[11]  E. Antman,et al.  Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. , 2004, European heart journal.

[12]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[13]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[14]  G. Fonarow,et al.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.

[15]  M. Simoons,et al.  Acute coronary syndromes complicated by symptomatic and asymptomatic heart failure: does current treatment comply with guidelines? , 2003, American heart journal.

[16]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[17]  M. Hori,et al.  Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.

[18]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[19]  M. Sabatine,et al.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.

[20]  J. Shepherd,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .

[21]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[22]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[23]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[24]  E. Braunwald,et al.  Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.

[25]  D. Morrow,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .

[26]  G. Fonarow,et al.  Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. , 2002, Journal of cardiac failure.

[27]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[28]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[29]  R. Laaksonen,et al.  The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. , 1996, The American journal of cardiology.